Prospects for Research in Hematologic Disorders
Sickle Cell Disease and Thalassemia
William C. Mentzer, MD;
Yuet Wai Kan, MD
JAMA. 2001;285:640-642.
Sickle cell anemia and thalassemia constitute the most common genetic diseases in the world. Affected patients carry a heavy burden of morbidity and early mortality. With improved understanding of the pathophysiology and molecular basis of these diseases, treatment is evolving from management of symptoms to more effective strategies that aim to modify diseased red blood cells or replace them with normal cells. Available treatment options include red blood cell transfusions, pharmacologic interventions to increase fetal hemoglobin levels, and stem cell transplantation. Improvements in these approaches or the development of means to replace defective genes with normal ones using techniques of gene transfer offer hope for the future.
Author Affiliations: Departments of Pediatrics (Dr Mentzer) and Laboratory Medicine (Dr Kan), Cardiovascular Research Institute, and Howard Hughes Medical Institute Laboratory, University of California, San Francisco.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
An Update on Anemia in Less Developed Countries
Tolentino and Friedman
Am J Trop Med Hyg 2007;77:44-51.
ABSTRACT
| FULL TEXT
Fetal hemoglobin modulation during human erythropoiesis: stem cell factor has "late" effects related to the expression pattern of CD117
Wojda et al.
Blood 2003;101:492-497.
ABSTRACT
| FULL TEXT
Novel Therapeutic Approaches in Sickle Cell Disease
Walters et al.
ASH Education Book 2002;2002:10-34.
ABSTRACT
| FULL TEXT
|
